United Therapeutics Chief Financial Officer, Edgemond, has executed a sale of company stock valued at $5.49 million. This transaction is part of the CFO's financial management activities and follows the company's recent performance in the market. The details of the stock sale, including the number of shares sold and the timing of the transaction, have been disclosed in compliance with regulatory requirements.
Related Articles
Don't miss out on breaking stories and in-depth articles.